ORGANIZING PNEUMONIA: AN ETIOLOGICAL DILEMMA IN PATIENTS ON RITUXIMAB FOR TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER

被引：0
|
作者：
Freeman, Howard
Zuckerman, Omry
O'Sullivan, Mary
机构：
来源：
CHEST | 2024年 / 166卷 / 04期
关键词：
D O I：
10.1016/j.chest.2024.06.3338
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：5626A / 5627A
页数：2
相关论文
共 50 条
  • [21] Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
    Wallach, Asya Izraelit
    Tremblay, Matthew
    Kister, Ilya
    NEUROLOGIC CLINICS, 2021, 39 (01) : 35 - 49
  • [22] Eculizumab in the treatment of neuromyelitis optica spectrum disorder
    Giglhuber, Katrin
    Berthele, Achim
    IMMUNOTHERAPY, 2020, 12 (14) : 1053 - 1066
  • [23] A case of neuromyelitis optica spectrum disorder complicated with aquaporin-4-antibody-associated organizing pneumonia
    Shibahara, Tomoya
    Yamanaka, Kei
    Matsuoka, Mikiaki
    Tachibana, Masaki
    Kuroda, Junya
    Nakane, Hiroshi
    MULTIPLE SCLEROSIS JOURNAL, 2025,
  • [24] Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data
    Altintas, A.
    Karabudak, R.
    Balci, B. Petek
    Terzi, M.
    Soysal, A.
    Saip, S.
    Kurne, A. Tuncer
    Uygunoglu, U.
    Nalbantoglu, M.
    Gozubatik-Celik, G.
    Isik, N.
    Celik, Y.
    Gokcay, F.
    Duman, T.
    Boz, C.
    Yucesan, C.
    Celebisoy, N.
    Diker, S.
    Isikay, I. C.
    Kansu, T.
    Siva, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 824 - 825
  • [25] Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
    Collongues, N.
    Marignier, R.
    Jacob, A.
    Leite, M. I.
    Sivas, A.
    Paul, F.
    Zephir, H.
    Akman-Demirs, G.
    Elsone, L.
    Jarius, S.
    Papeix, C.
    Mutch, K.
    Saips, S.
    Wildemann, B.
    Kitley, J.
    Karabudak, R.
    Aktas, O.
    Kuscu, D.
    Altintas, A.
    Palace, J.
    Confavreux, C.
    De Seze, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (08) : 1086 - 1094
  • [26] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [27] Depression in patients with neuromyelitis optica spectrum disorder
    Seok, J. M.
    Choi, M.
    Kim, Y. S.
    Cho, E. B.
    Lee, H. L.
    Kang, S. -Y.
    Lee, K. H.
    Kim, B. J.
    Min, J. -H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 94 - 94
  • [28] Immunoadsorption in patients with neuromyelitis optica spectrum disorder
    Faissner, Simon
    Nikolayczik, Johanna
    Chan, Andrew
    Gold, Ralf
    Yoon, Min-Suk
    Haghikia, Aiden
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (04) : 281 - 286
  • [29] Rituximab treatment in patients affected by neuromyelitis optica spectrum of disorder: long term safety and efficacy in clinical practice
    Radaelli, M.
    Moiola, L.
    Rodegher, M.
    Colombo, B.
    Barcella, V.
    Sangalli, F.
    Ferre, L.
    Fazio, R.
    Esposito, F.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 88 - 88
  • [30] Neuromyelitis optica spectrum disorder and rituximab: a multi-center analysis
    Novi, G.
    Capobianco, M.
    Gallo, F.
    Mataluni, G.
    Signori, A.
    Laroni, A.
    Annovazzi, P.
    Buttari, F.
    Rossi, S.
    Zuliani, L.
    Sica, F.
    Cocco, E.
    Benedetti, L.
    Malucchi, S.
    Frau, J.
    Sperli, F.
    Sormani, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 436 - 436
12345